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Abstract 
In the analysis of retrospective data or when interpreting results from a single-arm phase II clinical trial 
relative to historical data, it is often of interest to show plots summarizing time-to-event outcomes comparing 
treatment groups.  If the groups being compared are imbalanced with respect to factors known to influence 
outcome, these plots can be misleading and seemingly incompatible with results obtained from a regression 
model that accounts for these imbalances.  We consider ways in which covariate information can be used to 
obtain adjusted curves for time-to-event outcomes.  We first review a common model-based method and then 
suggest another model-based approach that is not as reliant on model assumptions.  Finally, an approach that 
is partially model free is suggested.  Each method is applied to an example from hematopoietic cell 
transplantation. 
Keywords: Cox regression, Kaplan-Meier, adjusted survival, cumulative incidence 
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1.  Introduction 
In the evaluation of time-to-event data derived from phase II clinical trials or retrospective 
studies in hematopoietic cell transplantation (HCT), Cox regression is typically used to 
quantify the difference in outcome between two groups.  Regression analysis allows one to 
adjust for potential imbalances in characteristics associated with outcome that might 
partially explain the difference (or lack thereof) between the groups being compared.  In 
addition to an estimate of the difference in outcome as derived from the regression model, it 
is often desirable to provide a graphical illustration of the difference.  The most common 
tool for this purpose is the Kaplan-Meier estimate for survival endpoints, and cumulative 
incidence estimate for endpoints with competing risks; however, neither of these estimates 
considers information from covariates that may be imbalanced among the groups, thereby 
leading to curves that may not reflect the differences among the groups as measured by the 
regression model.  A method to generate adjusted curves would therefore be desirable.  
Section 2 provides an example from HCT data and motivates the problem.  Section 3 
describes a relatively standard model-based approach, which illustrates the fitted model but 
falls short of achieving what we would consider to represent ‘adjusted survival’ curves.   
We then suggest a simple alternative that better accommodates the notion of adjustment, 
though still requiring some model assumptions.  Section 4 proposes a method that is less 
dependent on the model assumptions required of the methods summarized in Section 3, and 
is extended to provide adjusted cumulative incidence estimates in Section 5.  
2.  Example from HCT 
As an illustration of the problem we present an example from a retrospective data analysis 
that sought to compare outcomes after HCT following the use of nonmyeloablative 
conditioning to outcomes following conventional myeloablative conditioning in 220 
patients with B-cell malignancies [non-Hodgkin lymphoma (NHL), chronic lymphocytic 
leukemia (CLL), and Hodgkin lymphoma (HL)], as reported previously (Sorror et al. 2008).  
This comparison is complicated by a number of factors, chief among them the fact that 
nonmyeloablative conditioning is generally offered only to older patients and to patients 
with pre-existing comorbidity, who are generally considered to be unsuitable for transplant 
with myeloablative conditioning regimens.  There are also differences between these patient 
populations with respect to other factors that could influence outcome, including the 
diagnosis being treated, the use of mobilized peripheral blood (PBSC) versus bone marrow 
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(BM) as a source of stem cells, and the use of matched sibling versus mismatched or 
unrelated donor grafts.   Shown in Figure 1 are (unadjusted) Kaplan-Meier estimates of 
overall survival for the two conditioning groups. 
 
Table 1 summarizes the characteristics of the two conditioning groups plus the results from 
proportional hazards models relating these factors to overall mortality and non-relapse 
mortality (NRM), which is defined as any death occurring in the absence of recurrence or 
progression of malignancy.  As can be seen from this table, patients receiving 
nonmyeloablative conditioning are more likely to possess some factors that are associated 
with increased mortality when compared to patients receiving myeloablative conditioning.   
Although not all factors were associated with outcome in univariate analysis, they were 
considered as possible adjustment factors based on prior considerations and the possibility 
that an association was obscured by confounding factors. 
 
The results from an unadjusted Cox regression model show a modestly reduced hazard of 
mortality associated with nonmyeloablative conditioning relative to myeloablative 
conditioning [HR=0.77, 95% CI 0.5-1.4, p=0.20], as also evidenced by the curves in Figure 
1.  However, the HR for overall mortality adjusted for the factors in Table 1 suggests a 
much larger difference between the conditioning groups than is visually apparent 
[HR=0.50, 95% CI 0.3-0.8), p=0.008].  Given this, there is a need for some type of 
adjustment to the curves shown in Figure 1 so that the adjusted curves better reflect the 
association measured by the regression model.  In the next two sections, we discuss several 
approaches to adjustment.   
3.  Model-based Approaches 
We first introduce some notation that will be used throughout.  Suppose we have K groups 
of interest, with sample size in each group denoted nk, and sets of labels of the individuals 
within each group, denoted KkM k ,...,1, = .   Each individual i has a vector of additional 
covariates, zi, that may be related to overall survival or to some cause-specific hazard of 
interest.   
 
The Cox proportional hazards model assumes that the hazard of failure associated with a set 
of covariates z is defined by 
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                                 )exp()()|( 0 βλλ ztzt ′⋅=                                           (1) 
 
where )(0 tλ  is an arbitrary and unspecified baseline hazard function, and β  is a vector of 
unknown regression parameters.    Based on this model, the estimated survival for a 
particular set of covariates z is given by  
 
                                               [ ] )ˆexp(0 )(ˆ)|(ˆ βztSztS ′=                                            (2) 
 
where )](ˆexp[)(ˆ 00 ttS Λ−=  is derived from any standard estimate of the cumulative 
baseline hazard function (Kalbfleisch and Prentice 1980; Breslow 1974), and βˆ  is the 
vector of estimated coefficients from the Cox model. 
 
Under this model, one can use equation (2) to generate an estimate of survival for any 
specified set of covariates.  For the current example, a standard approach to illustrating the 
effect of the conditioning regimen “adjusted” for the other covariates, would be to fit a 
proportional hazards model incorporating all of the covariates in Table 1 plus an indicator 
of conditioning group.  Then (2) would be plotted for two z vectors differing only by the 
presence or absence of the indicator for conditioning, for example by using the 
“covariates=” option in the SAS “baseline” statement within the “phreg” procedure.  
For the factors listed in Table 1, one could assign the average value for patients in the 
myeloablative group, yielding the survival estimates in Figure 2.  
 
In our view, the adjusted curves that result from this model-based approach have some 
shortcomings.  First, the overall shape of the unadjusted Kaplan-Meier curves is not 
maintained.  This is due to the fact that the adjusted curves from (2) are derived from a 
pooled estimate of the common baseline hazard function, with the separation between 
curves dictated by the model-based hazard ratio estimate.  Even if the proportional hazards 
model is completely correct, the jump points of the adjusted curves will not match those of 
the unadjusted curves, because the jump points reflect deaths within either group.  While 
these curves accurately illustrate the fitted model, we believe they are too far removed from 
the unadjusted Kaplan-Meier curves to conform to the conventional notion of adjustment. 
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We propose a relatively simple adjustment method which results in jump points for the 
adjusted curve only when a death occurs within that group, so that the adjusted curve 
maintains its overall shape, although there is still dependence on a model-based hazard ratio 
comparing the two groups.  To implement the method one first chooses one of the K groups 
as the reference group, and then selects a time point tA as a point of reference for 
adjustment.  Ideally this point is well along the time axis to the right, but before the point 
where excessively large jumps may occur due to small numbers of patients at risk.   In a 
setting with two groups, suppose we choose M1 as the reference group, )(1ˆ tS  and )(ˆ2 tS  
denote the unadjusted Kaplan-Meier curves for M1 and M2, respectively, and πˆ  is the 
estimated adjusted hazard ratio comparing M2 to M1.   If )(
~
2 tS denotes the adjusted curve 
for M2, then we require this curve to satisfy 
 
                                                  ,)](ˆ[)(~ ˆ12
π
AA tStS =                                              (3) 
 
that is, at time tA we want the survival estimate for the adjusted curve for group 2 and the 
survival estimate for the reference group1 to be in accordance with the adjusted hazard ratio 
πˆ .   
 
One way to modify )(ˆ2 tS  to achieve this condition is to make a proportionate adjustment to 
the failure probability that yields the desired relationship at tA and then apply that to the 
entire curve, so that 
 
                                        )),(ˆ1)(/~(1)(~ 2222 tSmmtS −−=                                     (4) 
 
where ))](ˆ[1(~ ˆ12
π
AtSm −=  and )).(ˆ1( 22 AtSm −=   Although this adjustment method is 
based on the survival estimates at a single point in time, it produces reasonable results in 
many cases, although it is of course somewhat dependent on the choice of tA.  Also, if 
)(ˆ2 tS becomes small and the adjustment ratio 22 /~ mm  is large, then )(
~
2 tS  can be < 0.   In 
this case the proportionate adjustment could be based on the survival probability at tA, rather 
than the failure probability.  
 
6 
Another alternative to (4) that avoids this possibility is to solve for π~ to satisfy the 
relation ππ ˆ1
~
2 )](ˆ[)](ˆ[ AA tStS = . That is, π~ is the “effective hazard ratio” that would need to 
be applied to )(ˆ2 tS in order to achieve the desired survival probability at tA, and is easily 
solved as )](ˆlog[/)](ˆlog[ˆ~ 21 AA tStS⋅= ππ , with then π~22 )](ˆ[)(~ tStS = . 
 
In the example at hand we take tA to be 6 years, since it represents a point relatively far 
along in time yet short of where the curves become obviously unstable due to small 
numbers at risk, and again wish to use the myeloablative group as the reference group.  We 
have 399.0)6(1ˆ =S , and since πˆ  = 0.5 we want ,632.0399.0)6(~ 5.02 ==S  so that the 
adjusted failure probability 2~m = 0.368.  Since 473.0)6(ˆ2 =S , the unadjusted failure 
probability at tA is 2m = 0.527, and )(
~
2 tS  is constructed by mutiplying the failure 
probability in group 2 by a factor of 0.368/0.527 = 0.698 at all points in time.  The adjusted 
curve according to (4) is shown in Figure 3.   The alternate adjusted curve is obtained by 
using an effective hazard ratio 614.0)473.0log(/)399.0log(5.0~ =⋅=π applied to )(ˆ2 tS .  
The resulting curve is very similar to (4) except in the tail. 
 
As noted above, a drawback to this simple approach is the need to choose the timepoint tA.  
If the survival curves are based on groups with large sample sizes, and the risk sets do not 
get too small (< 10 patients per group, say), then the method is not particularly sensitive to 
the choice of time.  When the sample sizes are small, or there is clear non-proportionality of 
hazards, then the choice of tA becomes problematic and one should consider the method 
described below. 
4.  Partially Model-free Approach 
Although the methods described above produce adjusted curves that retain the same 
appearance as the unadjusted curves, they rely on a model-based estimate of the hazard 
ratio, including the assumption of proportional hazards between the groups of interest.  
They are also subject to some arbitrariness in the choice of the adjustment time tA. The 
method described below makes no modeling assumptions about the factor of interest, 
though it depends on modeling the hazards associated with the covariates to be adjusted for. 
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Using the notation above, a stratified proportional hazards model for this setting is defined 
by allowing the baseline hazard function to vary for each group, with other covariates 
modulating this hazard in a way that is common to all strata, as defined by 
 
                      ),exp()()( 0 βλλ ztt kk ′⋅=  .,...,1 Kk =                                  (5) 
 
Although in principle one or more components of β can be allowed to vary across strata, in 
the present context it makes little sense to talk about ‘adjustment’ unless it is presumed that 
the observed survival differences among the K groups are attributable to imbalances in 
covariates, not to differences in covariate effects. 
 
Given estimates of the λ0k and β, a standard estimate of the survival function for a member 
of group k, with arbitrary covariate vector z, is given by 
 
                 )},ˆexp()(ˆexp{)|(ˆ 0 βztztS kk ′⋅Λ−=  Kk ,...,1=                       (6) 
 
where )(ˆ 0 tkΛ  is any standard estimator of the cumulative baseline hazard function for 
group k in the context of a stratified proportional hazards model (Kalbfleisch and Prentice 
1980).  Now define a reference group of nA individuals with a specified set of covariates 
that will constitute a common point of adjustment; the set of labels for the individuals in 
this group is denoted MA.  In general we expect that MA would in fact be the same as one of 
the existing groups Mk, and mostly likely the reference group used in Cox regression 
analysis, but this is not essential and MA could instead represent some other defined 
population.   The adjusted survival function estimate for the kth group is simply the average 
of the estimated survival functions that would be obtained by applying (6) to each of the 
covariate vectors of the individuals in MA 
 
                    ∑ ∈⋅= − AMi ikAk ztSntS ),|(ˆ)(~ 1  .,...,1 Kk =                           (7) 
 
This approach to adjustment is somewhat similar to adjustment procedures described by 
Makuch (1982) and Chang et al. (1982); however, their methods used an unstratified 
proportional hazards model incorporating the group variable as a covariate.  Thus, like the 
standard approach described in Section 3, the adjusted curves are constrained to have the 
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same shape (which matches none of the unadjusted curves) and have a constant relationship 
determined by the fitted model.  Gail and Byar (1986) considered use of the stratified 
proportional hazards model for what they called “direct adjustment” of survival curves, due 
to the similarity to the concept of direct standardization in epidemiology.   The use of the 
stratified proportional hazards model frees the adjustment process of an unnecessary 
proportional hazards assumption for the groups of interest. The shape and jump points of 
the adjusted survival curves will match those of the corresponding unadjusted Kaplan-
Meier survival curves, and are free to cross.  Zhang et al. (2007) also discuss the stratified 
approach.  In fact, if KkMM kA ,...,1, == U  (i.e., the adjustment set comprises the entire 
dataset) then (7) is equivalent to their estimator (3).    
 
We apply this approach to the data associated with the above example, with the resulting 
curves shown in Figure 4, with MA corresponding to the group receiving myeloablative 
conditioning.   The adjusted curves now yield the hypothetical survival curves that would 
result if the patient characteristics of both groups had been that of the group receiving 
myeloablative conditioning.   The adjusted curve for the latter group, as should be expected, 
is very close to the original curve.  In fact, the visible separation observed here is larger 
than that typically seen when a group is adjusted to itself.  The method is easily 
implemented in SAS and we provide the requisite code in the Appendix.   A SAS macro 
that computes both estimates and standard errors when MA comprises the entire dataset can 
be found in Zhang et al. (2007). 
5.  Adjusted Cumulative Incidence Estimates 
In the transplant setting, it is also common to make comparisons of cause-specific hazards 
(for example, relapse and non-relapse mortality) and to graphically illustrate differences 
among groups with the use of cumulative incidence curves.  The same issues of adjustment 
arise when groups are imbalanced with respect to factors which may influence the cause-
specific hazards of interest, as would be true for the situation in Table 1. 
 
Suppose that j indexes the J types of events, let ti denote the event or censoring times for 
each individual, and let δi = j  indicate that the event that occurred at ti was of type j, with δi 
= 0 indicating that ti is a censoring time.  Then, the estimated cumulative incidence function 
for the jth type of event in the kth group may be written as 
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(Kalbfleisch and Prentice 1980) where the )(ˆ0 tSk  are the Kaplan-Meier estimates of “event-
free” overall survival within the kth group, and the JjtS jk ,...,1),(ˆ =  are the Kaplan-Meier 
estimates of “cause-specific” survival, i.e., the estimates obtained by censoring for other 
event types except j.  In general the latter are not interpretable, and are used here only as a 
device for computing the adjusted curves. The expression in brackets in (8) is an empirical 
estimate within group k of the conditional probability of a failure of type j at ti, more 
commonly written as an expression like dj(ti)/n(ti) (that is, the number of events of type j at 
ti divided by the number of subjects still at risk at ti); however, we have re-expressed this 
quantity by the equivalent representation using the cause-specific survivor functions. The 
adjusted estimator of the cumulative incidence function follows immediately by substituting 
the comparable adjusted estimator (7) for each of the )(ˆ tS jk in (8), yielding 
 
∑ =≤∈ −− ==−⋅= jttMi ijkijkikjk iik JjKktStStStI δ,: 0 ,...,1,,...1)],(~/)(~1[)(~)(~         (9) 
 
For example, )(~ 0 tSk is the adjusted version of event-free overall survival, computed using 
(7).  We assume that each of the adjusted components of (9) is adjusted for the same set of 
covariates, although of course the covariates may have different associations with each of 
the cause-specific hazards and with event-free survival.  The choice of the covariates to 
adjust for will depend on the particular cumulative incidence estimates that are of interest.  
An alternative formulation of (9), more in the spirit of (7), would first calculate individual 
estimates of cumulative incidence associated with each covariate vector zi in MA and then 
average these estimates, as defined by 
 
                         ∑ ∈− ⋅= AMi ijkAjk ztIntI )|(~)(~ 1                                        (10) 
where  ∑ =≤∈ −− −⋅= jttMl iljkiljkilkijk llk ztSztSztSztI δ,: 0 )]|(ˆ/)|(ˆ1[)|(ˆ)|(~  
 
and the )|(ˆ ztS jk are derived from stratified overall and cause-specific proportional hazards 
models, as in (6).  The adjusted estimators (9) and (10) are generally very close, but the 
computational algorithm for (9) is more straightforward and the one which we recommend.  
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Although we find the procedures give sensible results, neither strictly satisfies the relation 
∑ ==− Jj jkk tItS 10 )(~)(~1 , which would be true of the unadjusted estimates (8).  In most cases, 
however, the difference is negligible except possibly in the far right tail of the curves. 
 
Figure 5 illustrates the same data as used above, except that now we show curves for the 
cumulative incidence of non-relapse mortality, which accounts for 62 of the 114 total 
deaths.  The adjustment factors are the same as for overall mortality, and again MA 
represents the group receiving myeloablative conditioning.  The adjusted curve for the 
myeloablative group closely tracks the unadjusted curve, as should be expected.   Although 
the unadjusted curves are consistent with a lower rate of non-relapse mortality for the 
nonmyeloablative group [HR=0.65, 95% CI 0.4-1.1, p=0.10], the cumulative incidence 
adjusted to the covariate characteristics of the myeloablative group is notably lower than the 
unadjusted curve and better reflects the adjusted analysis [HR=0.28, 95% CI 0.1-0.6, 
p=0.0003]. 
6.  Discussion 
We have described several methods to obtain adjusted curves that summarize the 
probability of failure for time-to-event endpoints that commonly occur in HCT.  Other than 
the first of these methods (based directly on the Cox proportional hazards model), each has 
the desirable feature that the adjusted curves change only with failures within the relevant 
group, and the adjusted curves also maintain the shape that is seen in the appropriate 
unadjusted curve.  Regardless of the method used, it should be emphasized repeatedly that 
the adjusted curve is not “real”, is dependent on model assumptions, and is not in any way 
a surrogate for a properly designed prospective comparison.  We recommend that the 
unadjusted estimates always be shown for comparison, either in the same or a separate 
figure.  We argue, however, that the adjusted curves do make sense and visually provide a 
better reflection of the estimated differences among groups compared to use of the 
unadjusted curves.  There are likely other reasonable methods that would yield results that 
intuitively make sense as well.   
 
The methods in Section 3 provide similar results, at least for the example considered.  The 
method in Section 4 makes fewer model assumptions, and is not dependent on the choice of 
a time point to anchor the adjustment.  We also show how it can be extended to provide 
adjusted estimates of cumulative incidence curves.  Because of the general relationship 
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between cumulative incidence and cause-specific survival functions seen in (8), the 
methods in Section 3 could also be adapted to provide adjusted cumulative incidence 
estimates.  We have not evaluated the properties of such a procedure, however. 
 
While the model-based estimates differ a bit from the partially model-free estimates (and 
from each other), it is difficult to say that one is ‘correct’ and another ‘incorrect’ since, as 
emphasized above, the adjusted estimates are not real.  For the particular example 
considered, however, all methods resulted in adjusted curves that seem reasonable 
representations of the group differences as measured by the regression model.  In our 
experience, this has held true for other data sets as well, although in certain situations the 
estimates can differ by a fair amount in the tails, which is not unexpected.  Given that the 
partially model-free approach requires the fewest assumptions, we prefer its use over the 
other methods.  The model-based approach that is derived from π~22 )](ˆ[)(
~ tStS =  is very 
easy to implement, however, and would appear to be a reasonable approach as well. 
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Appendix 
SAS code for calculating adjusted Kaplan-Meier estimate according to (7). 
 
* generic data setup; 
data a;  
*   grp      stratification variable (eg 1=reference, 2=current); 
*   daysur   survival time; 
*   delsur   failure indicator; 
*   z1-z5    covariates to adjust for; 
 
* define reference covariate set as group 1; 
data ref; set a; if grp eq 1; 
 
* fit stratified Cox model, with covariate adjustment; 
* ‘estsurv’ is estimated survival for each member of reference set; 
proc phreg noprint data=a;  
 strata grp;  
 model daysur*delsur(0)=z1 z2 z3 z4 z5; 
 baseline out=b covariates=ref survival=estsurv/method=emp nomean; 
 
* average across the individuals in reference set at each time; 
* ‘adjkm’ is the adjusted Kaplan-Meier estimate; 
proc sort data=b; by grp daysur; 
proc univariate noprint data=b; by grp daysur;  
 var estsurv;  
 output out=c mean=adjkm; 
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Fig 1  Kaplan-Meier estimates of overall survival from aretrospective study in HCT.  The gray curve  
represents the probability of survival for patients who received a nonmyeloablative conditioning regimen, and 
the black curve represents the same for patients who received a myeloablative regimen.  Tick marks represent 
censored observations. 
 
Fig 2  Kaplan-Meier estimates and adjusted estimates of overall survival from a retrospective study in HCT.  
Solid curves represent the unadjusted (Kaplan-Meier) survival estimates for the two groups, dashed lines 
represent the adjusted estimates as determined from the appropriate Cox regression model.  Tick marks on the 
Kaplan-Meier curves represent censored observations. 
 
Fig 3  Kaplan-Meier estimates and adjusted estimates of overall survival from a retrospective study in HCT.  
Solid curves represent the unadjusted (Kaplan-Meier) estimates for the two groups, dashed lines represent the 
adjusted estimates from two different methods for the nonmyeloablative group.  The first dashed curve is 
obtained by proportionately changing the failure probability at each time; the second dashed curve is obtained 
by exponentiating the unadjusted curve to the appropriate power as detailed in Section 3.  Tick marks on the 
Kaplan-Meier curves represent censored observations. 
 
Fig 4  Kaplan-Meier estimates and adjusted estimates of overall survival from a retrospective study in HCT.  
Solid curves represent the unadjusted (Kaplan-Meier) survival estimates for the two groups; dashed lines 
represent the adjusted estimates obtained from the partially model-free approach detailed in Section 4. 
   
Fig 5  Cumulative incidence estimates and adjusted estimates of non-relapse mortality from a retrospective 
study in HCT.  Solid curves represent the unadjusted (cumulative incidence) non-relapse mortality estimates 
for the two groups, dashed lines represent the adjusted estimates obtained from the partially model-free 
approach detailed in Section 5. 
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Table 1.  Distribution of potential risk factors and their univariate association with overall 
mortality and non-relapse mortality from a Cox regression model. 
  
Ablative 
(n=68) 
Non- 
Ablative 
(n=152) 
Overall 
mortality 
(114 events) 
Non-relapse 
mortality 
(62 events) 
% % HR (95% CI) HR (95% CI) 
Diagnosis             NHL 
CLL 
HL 
79 
15 
6 
53 
27 
20 
Ref 
0.57 (0.3-0.9) 
0.88 (0.5-1.5) 
Ref 
0.62 (0.3-1.2) 
0.69 (0.3-1.5) 
HCT-CI                      0 
1,2 
3+ 
41 
26 
32 
30 
30 
40 
Ref 
1.66 (1.0-2.8) 
2.30 (1.4-3.7) 
Ref 
2.05 (1.0-4.2) 
2.99 (1.5-5.8) 
Donor                Sibling 
Other  
66 
34 
55 
45 
Ref 
0.98 (0.7-1.4) 
Ref 
1.07 (0.6-1.8) 
Source                PBSC 
BM 
69 
31 
99 
1 
Ref 
0.83 (0.4-1.6) 
Ref 
0.72 (0.3-1.8) 
Age                       < 50 
≥50 
82 
18 
41 
59 
Ref 
1.15 (0.8-1.7) 
Ref 
1.45 (0.9-2.4) 
Prior regimens        0-2 
3,4 
5+ 
56 
41 
3 
49 
37 
14 
Ref 
1.54 (1.1-2.2) 
0.74 (0.3-1.6) 
Ref 
1.44 (0.9-2.4) 
0.52 (0.2-1.7) 
Resistant Disease    No 
Yes 
34 
66 
49 
51 
Ref 
1.53 (1.0-2.3) 
Ref 
1.39 (0.8-2.3) 
Abbreviations:  NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; HL, 
Hodgkin lymphoma; HCT-CI, hematopoietic cell transplant – comorbidity index; BM, bone 
marrow; PBSC, peripheral blood stem cells. 
 
